我武生物(300357.SZ)上半年淨利1.3億元同比增25.53%
格隆匯8月14日丨我武生物(300357.SZ)披露2019年半年度報告,報告期內公司實現營業總收入2.74億元,同比增長25.43%;營業利潤1.50億元,同比增長23.06%;歸屬於上市公司股東的淨利潤1.30億元,同比增長25.53%;經營活動現金淨流入1.04億元,同比增長24.28%;基本每股收益0.2492元。
報告期內,業績增長主要原因是我國脱敏治療市場規模不斷擴大,公司主導產品銷售收入持續較快增長,管理效率持續優化,盈利水平較去年保持快速增長。報告期內,公司產品在國內華南、華中、華東等重點區域均實現較快增長,在大多數省級醫療機構藥品集中採購中中標,銷售網絡已進入到全國大多數省級城市和部分地縣級城市,患者規模不斷擴大。
2019年上半年,公司董事會按照年度經營計劃,繼續提升藥品的綜合研發能力,不斷完善公司產品在過敏性疾病領域的覆蓋能力,部分研發項目取得了階段性進展:完成了“黃花蒿粉滴劑”用於治療變應性鼻炎的多中心、隨機、雙盲安慰劑平行對照的III期臨牀試驗,並於2019年4月獲得了該產品的藥品註冊申請受理通知書;同時,報告期內完成了舌下含服“黃花蒿粉滴劑”對兒童變應性鼻炎患者的耐受性研究兒童I期臨牀試驗”;黃花蒿花粉點刺液、懸鈴木花粉點刺液等9項在研點刺產品的I期臨牀研究進展順利;“屋塵蟎皮膚點刺診斷試劑盒”獲得了國家藥品監督管理局核准簽發的《藥品註冊批件》和《新藥證書》,並於2019年7月收到浙江省藥品監督管理局頒發的《藥品GMP證書》。公司逐步形成了在過敏性疾病診療領域多種產品協同發展的格局。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.